Complement Mediated Diseases
1 clinical trials · Condition
◉ Watch Complement Mediated Diseases
| Record | Firm | Date |
|---|---|---|
| First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers (NCT03316521) | Amyndas Pharmaceuticals S.A. | 2017-04-24 |
Track Complement Mediated Diseases automatically
Every clearance here is in the API, with alerts when new ones post.